Zymeworks (ZYME) has released an update.
Zymeworks Inc., a biotech firm focused on multifunctional biotherapeutics, will release its Q2 2024 financial results on August 1, followed by a conference call and webcast. The company is notable for developing zanidatamab, a potential best-in-class treatment for HER2-positive cancers, with pending approvals in the U.S. and China.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
